Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Liabilities and Shareholders Equity (2017 - 2021)

Cogent Biosciences has reported Liabilities and Shareholders Equity over the past 5 years, most recently at $215.4 million for Q3 2021.

  • Quarterly results put Liabilities and Shareholders Equity at $215.4 million for Q3 2021, up 53.99% from a year ago — trailing twelve months through Dec 2021 was $681.5 million (up 47.9% YoY), and the annual figure for FY2020 was $250.9 million, up 407.69%.
  • Liabilities and Shareholders Equity for Q3 2021 was $215.4 million at Cogent Biosciences, down from $228.5 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for COGT hit a ceiling of $250.9 million in Q4 2020 and a floor of $31.1 million in Q2 2020.
  • Median Liabilities and Shareholders Equity over the past 5 years was $83.6 million (2018), compared with a mean of $111.0 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: tumbled 55.19% in 2020 and later skyrocketed 635.84% in 2021.
  • Cogent Biosciences' Liabilities and Shareholders Equity stood at $49.1 million in 2017, then soared by 74.95% to $85.9 million in 2018, then plummeted by 42.48% to $49.4 million in 2019, then skyrocketed by 407.69% to $250.9 million in 2020, then dropped by 14.16% to $215.4 million in 2021.
  • The last three reported values for Liabilities and Shareholders Equity were $215.4 million (Q3 2021), $228.5 million (Q2 2021), and $237.6 million (Q1 2021) per Business Quant data.